Literature DB >> 15843873

The emergence of modern cancer immunotherapy.

Steven A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15843873      PMCID： PMC2154347          DOI： 10.1245/ASO.2005.01.904

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  13 in total

Review 1.  Progress in human tumour immunology and immunotherapy.

Authors:  S A Rosenberg
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.

Authors:  Kathryn Spanknebel; Kenneth Y Cheung; John Stoutenburg; Karl Hurst-Wicker; Charles Hesdorffer; Gail Deraffele; Howard L Kaufman
Journal:  Ann Surg Oncol       Date:  2005-04-04       Impact factor: 5.344

5.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

6.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

7.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

8.  Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.

Authors:  U S Kammula; D E White; S A Rosenberg
Journal:  Cancer       Date:  1998-08-15       Impact factor: 6.860

9.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779
View more
  5 in total

1.  Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.

Authors:  R Taylor Ripley; Jeremy L Davis; Jacob A Klapper; Aarti Mathur; Udai Kammula; Richard E Royal; James C Yang; Richard M Sherry; Marybeth S Hughes; Steven K Libutti; Donald E White; Seth M Steinberg; Mark E Dudley; Steven A Rosenberg; Itzhak Avital
Journal:  Ann Surg Oncol       Date:  2009-09-24       Impact factor: 5.344

2.  Adaptive Immune Responses and HER2/neu Positive Breast Cancer.

Authors:  Eric D Mortenson; Yang-Xin Fu
Journal:  Curr Pathobiol Rep       Date:  2013-03

3.  Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.

Authors:  Ping Yu; Youjin Lee; Yang Wang; Xiaojuan Liu; Sogyong Auh; Thomas F Gajewski; Hans Schreiber; Zhaoyang You; Campbell Kaynor; Xinzhong Wang; Yang-Xin Fu
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

4.  Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.

Authors:  Melissa M Alvarez-Downing; Suzanne M Inchauste; Mark E Dudley; Donald E White; John R Wunderlich; Steven A Rosenberg; Udai S Kammula
Journal:  World J Surg Oncol       Date:  2012-06-22       Impact factor: 2.754

5.  Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion.

Authors:  Saleh Ayache; Monica C Panelli; Karen M Byrne; Stefanie Slezak; Susan F Leitman; Francesco M Marincola; David F Stroncek
Journal:  J Transl Med       Date:  2006-10-04       Impact factor: 5.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.